Christopher Ogden

Christopher Ogden appears in our data through filings on CytomX Therapeutics, Inc. shares, published by SEC (Form 4). We count 18 filings; the first trade dates from 2 February 2023 and the latest from 15 June 2026.

Every open-market trade on record is a sale: 9 sales worth €157k. Besides market trades, the filings include 6 share grants and 3 option exercises. 2026 to date brings no purchases and 2 sales.

Most recently, on 17 June 2026, the filings show an open-market sale worth €4,272 in CytomX Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.